LifeStance Health reports new anxiety medications are expected for 2026, featuring innovative treatments in clinical trials ...

Monoamine oxidase inhibitors were linked to the highest risk for cardiovascular Standardized MedDRA Queries. Dopamine reuptake inhibition and binding inhibition are linked to antidepressant-related ...

Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric ...

Synendos Therapeutics AG has received approval from the European Medicines Agency (EMA) to initiate a first-in-human trial of its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly ...

LOS ANGELES — The novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine (Otsuka Pharmaceutical Co., Ltd.) is effective and ...

Emerging evidence highlights psilocybin as a potential therapy for treatment-resistant OCD, while cannabinoids show limited efficacy.